Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 1, 2014

View Archived Issues

Clinical phase I/II results of gene therapy for Becker muscular dystrophy

Phase II clinical results for a three-drug combination against HCV infection

GlaxoSmithKline plans phase II study of GSK-2269557 for acute exacerbation of COPD

New antagonists of S1P3 revert neurodegeneration and neuroinflammation

Nippon Kayaku launches infliximab biosimilar in Japan

Osteopontin RNA aptamer shows potential for the treatment of heart failure

LCZ-696 granted accelerated assessment by CHMP in Europe

Fullerene polyaminocaproic acid tested against HSV infection

Medicines for Malaria Venture collaborates with Cipla and Strides

UCB and Daiichi Sankyo partner to commercialize lacosamide in Japan

Aerocrine plans rights issue to fund commercialization of asthma diagnostic

Bukwang Pharmaceutical acquires Contera Pharma

Fingolimod fails to achieve endpoint in phase III trial in PPMS

Rinat Neuroscience discloses new anti-glucagon receptor antibodies

Incyte patents novel JAK-1 inhibitors

Roche patent reports new anti-HBV compounds

New mu opioid receptor antagonists designed at Dr August Wolff

Suzhou Vivotide Biotechnologies discloses novel VEGFR-1 inhibitors

Dynavax regains rights to DV-1179 under GSK collaboration

Mochida seeks approval in Japan for Lexapro in social anxiety disorder

Janssen files for manufacturing and distribution approval for ibrutinib in Japan

MSD and Kyorin sign Japanese comarketing agreement for desloratadine

EMA accepts for review Imbruvica submission for Waldenstrom's macroglobulinemia

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...